Compare Stocks: DSGN, PGEN, GMTX, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$23.46 -4.0%	$26.50	$20.23 ▼ $38.26	$2.42B	2.2	2.04 million shs	779,175 shs
DSGN Design Therapeutics	$9.59 -2.0%	$13.73	$5.28 ▼ $17.25	$596.39M	1.68	598,957 shs	678,479 shs
GMTX Gemini Therapeutics	$56.60 -6.4%	$73.26	$1.16 ▼ $14.10	$2.45B	-0.12	189,291 shs	602,872 shs
PGEN Precigen	$7.61 +1.7%	$7.29	$3.04 ▼ $8.98	$2.72B	0.92	4.67 million shs	1.46 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-2.79%	-3.17%	+1.83%	-20.78%	-3.78%
DSGN Design Therapeutics	-10.36%	-18.30%	-33.15%	-27.66%	+50.69%
GMTX Gemini Therapeutics	-2.55%	-4.50%	-13.67%	-19.37%	-13.48%
PGEN Precigen	-2.35%	-0.93%	+9.20%	+46.09%	+133.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$23.46 -4.0%	$26.50	$20.23 ▼ $38.26	$2.42B	2.2	2.04 million shs	779,175 shs
DSGN Design Therapeutics	$9.59 -2.0%	$13.73	$5.28 ▼ $17.25	$596.39M	1.68	598,957 shs	678,479 shs
GMTX Gemini Therapeutics	$56.60 -6.4%	$73.26	$1.16 ▼ $14.10	$2.45B	-0.12	189,291 shs	602,872 shs
PGEN Precigen	$7.61 +1.7%	$7.29	$3.04 ▼ $8.98	$2.72B	0.92	4.67 million shs	1.46 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-2.79%	-3.17%	+1.83%	-20.78%	-3.78%
DSGN Design Therapeutics	-10.36%	-18.30%	-33.15%	-27.66%	+50.69%
GMTX Gemini Therapeutics	-2.55%	-4.50%	-13.67%	-19.37%	-13.48%
PGEN Precigen	-2.35%	-0.93%	+9.20%	+46.09%	+133.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.75	Moderate Buy	$50.10	105.08% Upside
DSGN Design Therapeutics	2.89	Moderate Buy	$17.86	82.59% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
PGEN Precigen	2.50	Moderate Buy	$13.67	82.71% Upside

Current Analyst Ratings Breakdown

Latest DSGN, PGEN, GMTX, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	PGEN Precigen	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
10/2/2026	DSGN Design Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$26.00
10/2/2026	DSGN Design Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$26.00
9/25/2026	PGEN Precigen	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$12.00
9/24/2026	PGEN Precigen	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$12.00
9/23/2026	BEAM Beam Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$65.00
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$80.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/5/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$14.00 ➝ $18.00
8/5/2026	PGEN Precigen	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	18.06	N/A	N/A	$12.20 per share	2.00
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
PGEN Precigen	$9.68M	275.49	N/A	N/A	$0.06 per share	124.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
PGEN Precigen	-$250.64M	-$1.04	N/A	10.25	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)

Latest DSGN, PGEN, GMTX, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	DSGN Design Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	BEAM Beam Therapeutics	-$1.15	N/A	N/A	N/A	$8.75 million	N/A
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
DSGN Design Therapeutics	N/A	18.86	18.86
GMTX Gemini Therapeutics	N/A	71.49	71.49
PGEN Precigen	2.15	4.58	3.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
DSGN Design Therapeutics	56.64%
GMTX Gemini Therapeutics	75.42%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
DSGN Design Therapeutics	17.10%
GMTX Gemini Therapeutics	12.90%
PGEN Precigen	41.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
PGEN Precigen	47	356.51 million	208.92 million	Optionable

DSGN, PGEN, GMTX, and BEAM Headlines

Recent News About These Companies

From Bethesda Magazine: Germantown biotech Precigen develops treatment for rare diseases

October 13 at 1:51 PM | bethesdamagazine.comB

Critical Comparison: Precigen (NASDAQ:PGEN) vs. Pyxis Oncology (NASDAQ:PYXS)

October 12 at 5:29 AM | americanbankingnews.com

Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Hold

October 7, 2026 | americanbankingnews.com

Precigen (NASDAQ:PGEN) Downgraded by Zacks Research to Hold

October 7, 2026 | marketbeat.com

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

October 5, 2026 | zacks.com

Precigen (NASDAQ:PGEN) Stock Falls 6.5% - Here's Why

October 5, 2026 | americanbankingnews.com

Precigen (NASDAQ:PGEN) Stock Falls 6.5% - What's Next?

October 5, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) versus Precigen (NASDAQ:PGEN) Head to Head Contrast

October 5, 2026 | americanbankingnews.com

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

October 2, 2026 | zacks.com

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

October 1, 2026 | zacks.com

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

September 30, 2026 | zacks.com

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

September 30, 2026 | finance.yahoo.com

Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect

September 30, 2026 | seekingalpha.com

Precigen (NASDAQ:PGEN) Hits New 12-Month High - Here's What Happened

September 30, 2026 | marketbeat.com

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

September 29, 2026 | finance.yahoo.com

Bank of America Corp DE Buys 1,848,414 Shares of Precigen, Inc. $PGEN

September 27, 2026 | marketbeat.com

Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?

September 26, 2026 | finance.yahoo.com

B Riley Securities initiates coverage of Precigen at buy

September 26, 2026 | msn.com

B. Riley Financial Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"

September 26, 2026 | marketbeat.com

Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies

September 26, 2026 | finance.yahoo.com

Precigen (NASDAQ:PGEN) Shares Gap Up - Here's What Happened

September 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, PGEN, GMTX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$23.46 -0.98 (-3.99%)

As of 12:44 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Design Therapeutics NASDAQ:DSGN

$9.59 -0.20 (-1.99%)

As of 12:43 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Gemini Therapeutics NASDAQ:GMTX

$56.60 -3.88 (-6.42%)

As of 10/13/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Precigen NASDAQ:PGEN

$7.60 +0.13 (+1.67%)

As of 12:44 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, PGEN, GMTX, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, PGEN, GMTX, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, PGEN, GMTX, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, PGEN, GMTX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Design Therapeutics NASDAQ:DSGN

Gemini Therapeutics NASDAQ:GMTX

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, PGEN, GMTX, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, PGEN, GMTX, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, PGEN, GMTX, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, PGEN, GMTX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Design Therapeutics NASDAQ:DSGN

Gemini Therapeutics NASDAQ:GMTX

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools